Compare BB & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BB | AGIO |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1999 | 2013 |
| Metric | BB | AGIO |
|---|---|---|
| Price | $3.56 | $34.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $4.90 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 7.9M | 851.4K |
| Earning Date | 04-09-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.91 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $534,900,000.00 | $43,011,000.00 |
| Revenue This Year | $4.19 | $74.95 |
| Revenue Next Year | $7.63 | $165.77 |
| P/E Ratio | $69.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.81 | $22.24 |
| 52 Week High | $5.32 | $46.00 |
| Indicator | BB | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.82 | 75.41 |
| Support Level | $3.55 | $26.64 |
| Resistance Level | $3.59 | $43.72 |
| Average True Range (ATR) | 0.12 | 1.36 |
| MACD | 0.04 | 0.74 |
| Stochastic Oscillator | 93.62 | 82.57 |
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.